Clinical use of non-A botulinum toxins: botulinum toxin type C and botulinum toxin type F

Neurotox Res. 2006 Apr;9(2-3):127-31. doi: 10.1007/BF03033930.


Botulinum neurotoxin (BoNT) serotype A is commonly used in the treatment of focal dystonia, but some patients are primarily or become secondarily resistant to it. Consequently, other serotypes have to be used when immuno-resistance is proven. In the literature, patients with focal dystonia have been treated with BoNT serotype F with clinical benefit but with short lasting effects. Recently, BoNT serotype C has been used with positive clinical outcome. An update on the clinical use of BoNT serotype F and BoNT serotype C is provided.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Animals
  • Blepharoptosis / drug therapy*
  • Blepharoptosis / physiopathology
  • Botulinum Toxins / therapeutic use*
  • Drug Resistance
  • Female
  • Humans
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Middle Aged
  • Muscle Weakness / drug therapy
  • Torticollis / drug therapy*
  • Torticollis / physiopathology


  • Botulinum Toxins
  • botulinum toxin type C
  • botulinum toxin type F